Skip to main content

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bayer Aktiengesellschaft (BAYRY)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Bayer Aktiengesellschaft ("Bayer" or the "Company") (OTC: BAYRY) American Depositary Receipts (“ADRs”) between May 23, 2016 and March 19, 2019, inclusive (the “Class Period”).

If you suffered a loss on your Bayer investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/bayer-aktiengesellschaft/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

In June 2018, Bayer acquired Monsanto Company ("Monsanto"), a provider of agricultural chemicals and other products.

On August 10, 2018, a jury found that Monsanto must pay $39 million in compensatory damages and $250 million in punitive damages, finding found that its Roundup weed killer was a "substantial factor" in causing the plaintiff to develop non-Hodgkin's lymphoma and that Monsanto knew, or should have known, the risks associated with exposure to the chemical and failed to warn of this severe health hazard.

On this news, the Company's share price fell $3.00, or 11%, to close at $23.59 per share on August 13, 2018.

Then, on March 19, 2019, another jury issued a verdict on causation, finding that plaintiff's "exposure to Roundup was a substantial factor in causing his non-Hodgkin's lymphoma."

On this news, the Company's share price fell $1.82, or 9%, to close at $17.85 per share on March 20, 2019, on unusually heavy trading volume.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose: (1) that the acquisition of Monsanto would cause the Company to suffer from exposure to massive judgements and reputational damage if lawsuits related to Monsanto's Roundup product were successful; (2) that the Company's positive statements about the prospects of the Monsanto acquisition and the benefits it would create were false; (3) as a result, the Company's public statements throughout the class period were false and materially misleading.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Bayer ADR’s during the Class Period, you may move the Court no later than September 14, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.